PARIS, France—While failing to reduce the number of new cerebral lesions after transcatheter aortic valve replacement (TAVR), a unique embolic deflection device does reduce the volume of such lesions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback